Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad-p53 with Capecitabine or PD-1 Inhibitors in Advanced Cancer
NCT02842125Phase 2Terminated
- Sponsor
- MultiVir, Inc.
- Start
- Nov 2018
- Primary completion
- May 2020
- Modality
- Gene Editing, Gene Silencing, Viral Vectors
- Countries
- 1
01
Overview
Phase 2, open-label trial of Ad5CMV-p53 in colorectal cancer (CRC), hepatocellular carcinoma (HCC), head and neck squamous cell carcinoma (HNSCC) and 1 more (3 arms), sponsored by MultiVir, Inc. Primary endpoints: Safety assessed by CTCAE up to 22 weeks, Incidence of dose-limiting toxicities up to 21 weeks and 2 more. Started Nov 2018; status: terminated.
02
Drugs
Ad5CMV-p53
03
Conditions
colorectal cancer (CRC)hepatocellular carcinoma (HCC)head and neck squamous cell carcinoma (HNSCC)solid tumor
Beyond the preview
Go deeper on NCT02842125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02842125.